The top two U.S. defense contractors lifted their full-year financial guidance, citing surging orders and growing backlogs as the Pentagon replenishes stockpiles amid global conflicts.
Shares of the telehealth company (NYSE: HIMS) rose after a U.S. FDA advisory committee voted 8-6 to recommend expanded access for the compound, a positive but non-binding step for its potential use.
France has become the first EU member state to publicly reject a Dutch-led proposal for the approval of Tesla's Full Self-Driving (FSD) software, with its transportation minister citing significant safety risks.
Shares of the telehealth company jumped after a U.S. FDA advisory committee recommended expanding access to the BPC-157 peptide, signaling a potential new market for wellness treatments.
French renewable energy firm Voltalia reported a significant revenue increase for the second quarter, driven by new capacity and favorable pricing, though it slightly trimmed its year-end capacity target.
CSX shares rallied against a falling market after the railroad operator posted second-quarter earnings and revenue that beat analyst estimates and raised its full-year guidance.
Jes Staley, the former chief executive of Barclays, is scheduled to appear in a closed-door session before a U.S. House committee as part of its ongoing investigation into the late financier Jeffrey Epstein's network.
Eli Lilly announced it will push back the regulatory filing for its promising obesity treatment, retatrutide, to the first quarter of 2027, citing the need for more manufacturing data, even as new Phase 3 trials showed significant weight loss.
Quarterly results from Alphabet and Tesla revealed a massive cash burn driven by soaring AI-related capital expenditures, sparking a broad tech sell-off and raising investor concerns about the profitability of the AI boom.
